Vendor Intelligence Report: Guangzhou yunyu trading

Published 3 Jul 2026. 19-page investigative report on who is behind Guangzhou yunyu trading: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Guangzhou yunyu trading shows 4 pass / 0 fail, for an overall pass rate of 100%. That clean result is meaningful, but narrow: Finnrick's record covers Retatrutide only. For a Retatrutide buyer, this vendor belongs in the comparison set; for Tirzepatide, Semaglutide, Cagrilintide, or the broader catalog, the public evidence remains extrapolation. The methodology-divergence exhibit shows why stricter purity and fill assumptions still matter.

The counterparty file is where the risk concentrates. The live site presents manufacturer, laboratory, and overseas-warehouse claims, yet accessible checks did not verify the legal entity, registered office, named responsible officer, facility, or warehouse network. The sales surface is a generic Gmail address and WhatsApp-first channel, so buyers need channel authentication, lot-specific COAs, and payment-beneficiary checks before treating a passing Retatrutide record as transaction safety.

The investigation also found discontinuity clues around the brand story. A 2014 export record for a near-name Guangzhou Yunyu commerce entity points to display fixtures shipped to Canada, not peptides. Infrastructure work found a sister peptide storefront sharing the same IP address, xuansiwei platform, and catalog while using different contacts and payment rails; reputation captures from GridinSoft and ScamAdviser were severe, and archive history remained thin.

Inside the full report:

  • Appendix A Retatrutide lab data and methodology-divergence charts
  • Homepage, About Us, and Product Center snapshots documenting manufacturer and warehouse claims
  • Infrastructure analysis of IP 104.238.133.163, xuansiwei platform use, DNS changes, and luckypeptide.com overlap
  • SEAIR 2014 export-record analysis contrasting display-fixture exports with current peptide claims
  • GridinSoft and ScamAdviser reputation captures, plus forum, X, and coupon-promotion sweep results
  • Buyer-risk matrix covering corporate identity, COA verification, channel authentication, and non-Retatrutide catalog limits

Risk assessment

  • Corporate-identity and claimed-manufacturer risk — high: Claimed legal entity and ownership were not verified; the site uses Gmail and a +852 WhatsApp, while manufacturer and warehouse claims lack corroboration.
  • Shared storefront and brand-confusion risk — high: Luckypeptide shares IP 104.238.133.163, the xuansiwei platform, and the catalog, but uses different contacts and crypto payment rails; official-channel verification is absent.
  • Domain reputation and continuity risk — high: GridinSoft rates yunyushangmao.top 1/100 and ScamAdviser 0/100; DNS and hosting records show a young shared .top storefront with limited archive continuity.
  • Batch-documentation and COA verification risk — high: Product pages claim 99%+ purity but public lot-specific COAs and pricing were not found; Retatrutide buyers still need lot-level verification.
  • Untested non-Retatrutide catalog risk — medium: Finnrick has tested only Retatrutide, with 4 tests, 4 pass / 0 fail, and an 83.04% rating; Tirzepatide, Semaglutide, Cagrilintide, and other catalog items lack product-specific Finnrick support.